Form 4: Prime Medicine Executive Gottesdiener Acquires 100,000 Shares Following Milestone Achievement

Keith Michael Gottesdiener, a director and officer at Prime Medicine, Inc., acquired 100,000 shares of common stock via stock option vesting after a performance milestone was met.

Summary

• Keith Michael Gottesdiener, a director and officer of Prime Medicine, Inc., filed a Form 4 disclosing a transaction on May 8, 2025.
• The transaction involved the vesting of a stock option for 100,000 shares of Prime Medicine's common stock.
• This vesting occurred because a performance milestone condition was achieved, as determined by the company's board of directors.
• The option was initially granted on February 25, 2024, with a portion of the shares vesting upon achieving certain performance milestones.
• The exercise price of the stock option is $8.32.
• Following the transaction, Gottesdiener beneficially owns 300,000 derivative securities.
• A Limited Power of Attorney was also filed, granting certain individuals the authority to execute SEC forms on behalf of Gottesdiener.

Sentiment

Score: 7

Explanation: The document is generally positive as it indicates that a performance milestone was achieved, leading to the vesting of stock options for a key executive. This suggests progress and alignment of management incentives.

Positives

• The vesting of the stock option suggests that Prime Medicine is achieving its performance milestones.
• Gottesdiener's increased stake in the company could be seen as a positive sign of confidence in Prime Medicine's future prospects.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance beyond the vesting schedule of the stock options.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The vesting of stock options is a common incentive mechanism used to align the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option plans are a standard component of compensation packages for executives in the biotechnology industry, similar to companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics.
• Vesting schedules tied to performance milestones are also common, designed to incentivize specific achievements and drive company growth.

Stakeholder Impact

• Shareholders may view the achievement of performance milestones and the increased stake of a key executive as a positive sign.
• Employees may be motivated by the company's progress and the alignment of executive incentives with company goals.

Key Dates

Keywords

Form 4, Prime Medicine, Stock Option, Vesting, Beneficial Ownership, Gottesdiener, Performance Milestone